"INVESTIGATION of the EFFICACY and SAFETY of the DRUG AS-PROBIONORM"

PHASE2CompletedINTERVENTIONAL
Enrollment

210

Participants

Timeline

Start Date

July 22, 2024

Primary Completion Date

August 11, 2024

Study Completion Date

August 11, 2024

Conditions
Intestinal InfectionsDysbacteriosis
Interventions
DRUG

"AS-Probionorm"

"Phase II of the clinical trial of the medicine included 210 study subjects with identified clinical and/or microbiological signs of dysbiosis. 3 groups of 70 research subjects will be formed.~Group 1 - study subjects with an identified decrease in intestinal microflora activity; Group 2 - study subjects with an identified fungal (candidiasis) infection; Group 3 - study subjects with active pathogenic microflora.~Dosage regimen for first group - 1 sachet (1 g) 2 times a day (morning and evening) 15 min prior food , with an interval of 12 hours. The total duration of study subjects' participation in the study is 28 days. Dosage regimen for the second and third groups - 2 sachet (2 g) 2 times a day (morning and evening) 15 min prior food , with an interval of 12 hours. The total duration of study subjects' participation in the study is 28 days."

Trial Locations (1)

Unknown

MIPO Clinic LLP, Almaty

All Listed Sponsors
lead

Industrial Microbiology LLP

OTHER

NCT06886399 - "INVESTIGATION of the EFFICACY and SAFETY of the DRUG AS-PROBIONORM" | Biotech Hunter | Biotech Hunter